Merck Announced On Saturday That KEYTRUDA Reduced The Risk Of Death By 38% Compared To Placebo As Adjuvant Therapy For Patients With Renal Cell Carcinoma (RCC) At An Increased Risk Of Recurrence Following Nephrectomy
Portfolio Pulse from Benzinga Newsdesk
Merck's KEYTRUDA has shown a 38% reduction in the risk of death compared to placebo in a Phase 3 trial as adjuvant therapy for RCC patients post-nephrectomy. These results were featured in the Press Program at the 2024 ASCO Genitourinary Cancers Symposium.
January 29, 2024 | 5:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's KEYTRUDA shows significant survival benefit in RCC, which may boost its market position and potentially increase future revenues.
The positive results from the KEYTRUDA trial are likely to enhance Merck's reputation in oncology treatments, potentially leading to increased demand and sales for KEYTRUDA. This could have a favorable impact on Merck's stock price in the short term as investors may anticipate growth in revenue from this successful trial outcome.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100